Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

THE PROPOSED MOA STORY*

Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

In vitro, NUPLAZID is a serotonergic agent* with no appreciable affinity for dopaminergic, histaminergic, muscarinic, or adrenergic receptors1

NUPLAZID® (pimavanserin) Receptor Affinity

The precise mechanism of action of NUPLAZID in the treatment of hallucinations and delusions associated with PD psychosis is unclear. However, the effect of NUPLAZID could be mediated through the combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.1 Lower Ki numbers indicate a greater binding affinity and thus a smaller amount of the drug is needed to block activity.

Proposed mechanism of action for NUPLAZID1*

Watch this video to learn more about the proposed mechanism of action for NUPLAZID.

The precise mechanism of action of NUPLAZID in the treatment of hallucinations and delusions associated with PD psychosis is unclear. However, the effect of NUPLAZID could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.

For healthcare professionals